Breaking down Barriers to Precision Medicine

We are expanding the reach of precision medicine by providing unprecedented resolution into disease-defining biology from a simple blood test.

ABOUT US

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, at Precede Biosciences, we've developed a platform that uncovers actionable disease-defining transcriptional biology from a simple blood test. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

our SCIENCE

Our first-in-class liquid biopsy platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma. This genome-wide, feature-rich space of ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands gives us resolution into the dynamic activation of individual genes and pathways.

Our first-in-class liquid biopsy platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma. This genome-wide, feature-rich space of ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands gives us resolution into the dynamic activation of individual genes and pathways.

01

02

03

04

05

It starts in the clinic with a simple blood draw

We profile transcriptional biology using sophisticated molecular techniques

And apply proprietary machine learning approaches

To give you interpretable and actionable readouts

Expanding the universe of precision medicine

Expanding the universe of precision medicine

our Team

We are a mission-driven, collaborative, energetic team of proven experts in the fields of liquid biopsy development, computational biology, transcriptional regulation, and the translational sciences.

leadership

Team

sab

bod

Investors

leadership

Jessica Alfano, Esq.

Jessica Alfano, Esq.

Senior Corporate Counsel

J. Carl Barrett, Ph.D.

J. Carl Barrett, Ph.D.

Chief Scientific Officer, Scientific Advisory Board

Juliann Chmielecki, Ph.D.

Juliann Chmielecki, Ph.D.

Vice President, Translational Sciences

Kristian Cibulskis

Kristian Cibulskis

Senior Director, Head of Bioinformatics Engineering

Travis Clark, Ph.D.

Travis Clark, Ph.D.

Vice President, Product Development

Matthew Eaton, Ph.D.

Matthew Eaton, Ph.D.

Vice President, Computational Biology

Jennifer Fortune

Jennifer Fortune

Chief Operating Officer

Eric Kaldjian, MD

Eric Kaldjian, MD

Medical Advisor

Eve Kretschmer, MBA

Eve Kretschmer, MBA

Vice President, Corporate Development

Adrian Li, Ph.D.

Adrian Li, Ph.D.

Associate Director, Corporate Strategy and Operations

Geoff Otto, Ph.D.

Geoff Otto, Ph.D.

Chief Product Development Officer

Corrie Painter, Ph.D.

Corrie Painter, Ph.D.

Vice President, External Research and Partnerships

Kori Rahaim, MBA

Kori Rahaim, MBA

Vice President of People

Fernando Ramirez

Fernando Ramirez

Director, Head of Lab Automation

Rehan Verjee

Rehan Verjee

Co-Founder, Chief Executive Officer, Board of Directors

TEAM

Jonathan Beagan, Ph.D.

Scientist, Computational Biology & Bioinformatics

Michael Coyne, M.S.

Associate Director, Development Operations

Anthony D'Ippolito, Ph.D.

Senior Scientist, Computational Biology & Bioinformatics

Amy Donahue, M.S.

Senior Scientist, Product Development

Garrett Gilman

Associate Director, Facilities & Operations

Aparna Gorthi, Ph.D.

Associate Director, Translational Sciences

Mandy Greene

Senior Scientist, Product Development

Jamey Guess, M.S.

Senior Scientist, Computational Biology & Bioinformatics

Hyun-Hwan Jeong, Ph.D.

Senior Scientist, Computational Biology & Bioinformatics

Alyssa Lau, Ph.D.

Senior Scientist, Product Development

Anatoly Myaskovsky

Senior Automation Engineer, Product Development

Khoi Nguyen

Senior Scientist, Computational Biology

David Rawling, Ph.D.

Principal Scientist, Product Development

Hathairat Sawaengsri, Ph.D.

Associate Director, Clinical Program Management

Tyrone Tamakloe

Scientist, Development Operations

Baovy Tran

Scientist, Development Operations

Mike Zhong, MS

Principal Software Engineer

SAB

Sylvan Baca, MD, Ph.D.

Co-Founder of Precede; Assistant Professor of Medicine, Dana-Farber Cancer Institute

Sylvan Baca, MD, Ph.D.

Co-Founder of Precede; Assistant Professor of Medicine, Dana-Farber Cancer Institute

Close Button

J. Carl Barrett, Ph.D.

Chief Scientific Officer, Scientific Advisory Board

J. Carl Barrett, Ph.D.

Chief Scientific Officer, Scientific Advisory Board

Carl is a renowned professional in the field of translational medicine and diagnostics with over 17 years of experience in drug development and technology advancement. In his previous role as the Vice President and Head of Oncology Translational Medicine at AstraZeneca Pharmaceuticals, he led a global team, spearheading biomarker strategy and translational sciences to support oncology drug development. Carl’s career also includes leadership positions at Novartis Institutes for BioMedical Research and the National Cancer Institute. He has made significant contributions to the field, with over 600 publications to his name and a reputation for mentoring future leaders in the pharmaceutical and biomedical sectors. Driven by a passion for lifelong learning and effective communication, he continues to shape the landscape of healthcare innovation. He holds a Ph.D. in Biophysical Chemistry from The Johns Hopkins University and a B.S. in Chemistry from the College of William and Mary.

Close Button

Toni Choueiri, MD

Co-Founder of Precede; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute

Toni Choueiri, MD

Co-Founder of Precede; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute

Close Button

Matthew Freedman, MD

Co-Founder of Precede; Professor of Medicine, Dana-Farber Cancer Institute

Matthew Freedman, MD

Co-Founder of Precede; Professor of Medicine, Dana-Farber Cancer Institute

Close Button

Joseph Loscalzo, MD, Ph.D.

Professor of Theory and Practice of Medicine, HMS; Chairman of Department of Medicine, Brigham and Women’s Hospital

Joseph Loscalzo, MD, Ph.D.

Professor of Theory and Practice of Medicine, HMS; Chairman of Department of Medicine, Brigham and Women’s Hospital

Close Button

Daniel Marshak, Ph.D.

Previously CSO, PerkinElmer

Daniel Marshak, Ph.D.

Previously CSO, PerkinElmer

Close Button

Olga Troyanskaya, Ph.D.

Professor of Computer Science and Genomics, Princeton University

Olga Troyanskaya, Ph.D.

Professor of Computer Science and Genomics, Princeton University

Close Button

BOD

Judith Li, MBA

Partner, Lilly Asia Ventures

Judith Li, MBA

Partner, Lilly Asia Ventures

Alex Parker, Ph.D.

Independent Advisor; Previously Vice President, Business Development, Foundation Medicine

Alex Parker, Ph.D.

Independent Advisor; Previously Vice President, Business Development, Foundation Medicine

Kush Parmar, MD, Ph.D.

Managing Partner, 5AM Ventures

Kush Parmar, MD, Ph.D.

Managing Partner, 5AM Ventures

Rehan Verjee

Co-Founder, Chief Executive Officer, Board of Directors

Rehan Verjee

Co-Founder, Chief Executive Officer, Board of Directors

Rehan is the founding CEO of Precede Biosciences. Prior to co-founding Precede Bio, Rehan was a member of the Healthcare Executive Committee at Merck KGaA from October 2015 to March 2021. During this time, Rehan served as the President of EMD Serono and as the Chief Marketing and Strategy officer. In these roles, Rehan was responsible for growing the global, multi-billion dollar specialty medicine franchises of oncology, neurology, immunology and infertility, which included leading and transforming the North American business, co-chairing the R&D development committee (responsible for all R&D decisions from Phase 1 to approval), leading global business development, chairing significant global R&D alliances, and having responsibility for the launches of new medicines across the major markets of the USA, the EU, China and Japan. Rehan is currently a member of the board of directors of Tyra Biosciences and the Massachusetts Biotechnology Council, and he holds a Master's degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.

Richard Young, Ph.D.

Member, Whitehead Institute; Professor of Biology, MIT

Richard Young, Ph.D.

Member, Whitehead Institute; Professor of Biology, MIT

Investors

Dana-Farber Logo
5am Ventures Logo
Bristol Myers Squibb Logo
Illumina Ventures Logo
OUP Logo
Lilly Asia Ventures Logo
Qatar Investment Authority Logo

PARTNER WITH US

We are actively working with developers of new medicines to elucidate the biology behind treatment response and resistance and to identify new targets that are mechanistically linked to disease.

If you think our platform could make a difference to your medicine in development or your research problem, get in touch with us.

JOIN US

At Precede Biosciences, we believe hard problems are best solved when we’re working side by side as a team of capable, inspired, mission-driven colleagues that trust and genuinely care about one another. We also believe that every person on the team is essential to our success and that every one of us has the potential to change the fabric of the company, and the world, for the better. If this resonates, and you think you can contribute, then apply to an open position.

A wave of water

Get in touch

1 Design Center Place, Suite 19-500, Boston, MA 02210

617.356.1457

We use cookies to provide the content and functionality of this website, and subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie notice for more information